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Abstract Background. Previous studies have suggest-
ed that hyperhomocysteinemia may be a risk factor for
venous thrombosis. Tb assess the risk of venous throm-
bosis associated with hyperhomocysteinemia, we stud-
ied plasma homocysteine levels in patients with a first
episode of deep-vein thrombosis and in normal control
subjects.
Methode. We measured plasma homocysteine levels
in 269 patients with a first, objectively diagnosed epi-
sode of deep-vein thrombosis and in 269 healthy con-
trols matched to the patients according to age and sex.
Hyperhomocysteinemia was defined äs a plasma ho-
mocysteine level above the 95th percentile in the control
group (18.5 μηιοί per liter).
Results. Of the 269 patients, 28 (10 percent) had plas-
ma homocysteine levels above the 95th percentile for the
controls, äs compared with 13 of the controls (matched
odds ratio, 2.5; 95 percent confidence interval, 1.2 to 5.2).
The association between elevated homocysteine levels
and venous thrombosis was stronger among women than
among men and increased with age. The exclusion of
subjects with other established risk factors for thrombosis
(e.g., a deficiency of protein C, protein S, or antithrombin;
resistance to activated protein C; pregnancy or recent
childbirth; or oral-contraceptive use) did not materially af-
fect the risk estimates.
Conclusions. High plasma homocysteine levels are a
risk factor for deep-vein thrombosis in the general popu-
lation. (N Engl J Med 1996;334:759-62.)
©1996, Massachusetts Medical Society.
MILD hyperhomocysteinemia is an established riskfactor (or atherosclcrosis and vascular disease.1·-
In ciassic homocystinuria, half the vascular complica-
tions are of venous origin,:ibut until reccntly it has bcen
unclear whether mild hyperhomocysteinemia is also a
risk factor for venous thrombosis.2·1'5 In a casc—control
stucly, Falcon et al. found that hyperhomocysteinemia
was Ά risk faclor for thrombosis in people younger than
40 years of agc.(> They rcportecl that the diffcrcncc in
homocysteine levels between casc patients and control
subjects was particularly evident after mcthionine load-
ing (sincc mcthionine is a prccursor of homocysteine).
Recently, wc found hyperhomocysteinemia to bc a risk
factor for recurrcnt venous thrombosis in patients bc-
twecn 20 and 70 years of age, äs compared with controls
from the gcncral population.7 Although the results of
thcse studies support the hypothesis that mild hyperho-
mocysteinemia is a risk factor for venous thrombosis,
the studies werc not designed to cstimate the risk in the
general population.
Wc measured homocysteine conccntrations in paticnls
and matched control subjccls participating in the Leiden
Thrombophilia Study.8"" This is a population-based
casc-control study designed to measure the effect ofsev-
eral acquired and genetic risk factors for thrombosis in
the general population. Bccause of the data available
on the study subjects, we were ablc to investigatc wheth-
er the effect of hyperhomocysteinemia was independent
of other well-established risk factors for thrombosis,
such äs a deficiency of protein G, protein S, or anti-
thrombin; use of oral contraccptivcs; and pregnancy or
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recent childbirth. Recently, resistance lo activated pro-
lein G caused by a single point mutation in the factor
V gcnc (factor V Leiden) has been rcported to bc the
most common hercditary cause of venous thrombosis.12
Since hyperhomocysteinemia also appears to bc com-
mon, we cxamincd the risk of thrombosis in pcrsons with
both abnormaliücs.
METHODS
The methods by which blood samples were obtained and intervic\\'
data werc colleeted have been described elsewhcre.^" The stndy pro-
tocol was approved by the local elhics committce, and all participants
gave thcir informed conscnt. Brietty, consccnlivc patients youngcr
ihan 70 years of age wbo had a first episode of deep-vein thi ombosis,
objcclivcly confirmcd (by impedancc plcthysmography, Dopplcr ul-
trasonography, compression ultrasonography, or conlrasl venogra-
phy), between 1988 and 1993 and who had no known cancer were sc-
lected from the tiles of three anticoagulation clinies in the Netherlands
(in Leiden, Amsterdam, and Rotterdarn). These chnics monitor the
anticoagulant trcatmcnt of virtually all patients in well-dcfincd geo-
graphic areas. Each patient was askcd to find bis or her own healthy
control subject of the samc sex and age (within fwe years) by asking
neighbors or friends. Wc restricted the prcscnl analysis to casc pa-
tients and controls who were seen at the Leiden Anticoagulation Clin-
ic and whose blood samples werc processed and frozcn on site with
minimal dclay. (Blood samples from participants in Amsterdam and
Rotterdam were also processed in Leiden, which caused delays of sev-
eral hours, and homocysteine measuremcnls were therefore less accu-
ratc than those measured in samples from subjects in Leiden.15)
The total homocysteine conccntration was measured in citrated
plasma by automatcd high-performancc liquid chromatography with
reverse-phase Separation and fluoresccnt detection (witb a Gilson 232-
401 sample processor, Spcctra-Physics 8800 solvent-delivery system,
and Spcctra-Physics LC 304 fluorometer). Wc used the method de-
scribed by Fiskcrstrand et al.Li with somc modifications.'' If not other-
wisc stated, hyperhomocysteinemia was defined äs a homocysteine lev-
cl above the 95th percentile in the control group (18.5μιτκ>1 per liter).
Wc calculated matched odds ratios äs estimates of the relative risk
of thrombosis for homocysteine values above a given point, with the
matching factor takcn into account. The univariate matched odds ra-
tio is the ratio of the number of pairs of case patients and controls in
which the homocysteine valne for the casc patient was above the spec-
ificd level and the value for the control was below that level to the
number of pairs in which the homocysteine value for the conlrol was
above the spccified level and the value for the case patient was bclow
that level. The 95 percent confidence intervals werc calculated from
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a conditional logislic-regression algorithm by thc maximum-likcli-
hood method, with Egret Software. We also invcstigated a possiblc
dosc-rcsponse rclation by calculating odds ratios for several ranges of
homocyslcinc concentrations in a conditional logistic model. In aclcli-
tion, we calculated odds ratios for men and women separately and for
several age groups in order to study possiblc diffcrenccs in risk among
thcsc subgroups.
Wc further explored the differences in risk between men and wom-
cn by taking risk factors specific to women into account — specifical-
ly, the use of oral contraccptivcs, prcgnancy, and rccent childbirth.
We analyzed the risk of thrombosis among womcn less lhan 50 ycars
old, both with and without thc inclusion of womcn with thesc risk fac-
tors, by calculating unmatchcd odds ratios. The use of unmalchccl
odds ratios was necessary because in thc restricted groups many
matchcd pairs would not havc been complete. Sincc the matchcd and
unmatched odds ratios diel not diffcr substantially in any oi our anal-
yscs, we considered this approach justiiicd.
Wc also assessed whcthcr thc increased risk associatcd with hyper-
homocysteinenna in both sexes was confoundcd by othcr risk factors,
such äs a dcficicncy of protein C, protein S, or antithrombin. Wc rc-
peatcd the analysis alter cxcluding subjccls with abnormally low lev-
els of thesc protcins (mcasurcd, äs prcviously reported, with a single
lest") and estimatcd thc risk associalcd will) hypcrhomocystcincmia
in pcrsons with normal protein C, protein S, and antilhrombin Icvcls.
Finally, wc looked at the possibility of an intcraction bctwccn hy-
pcrhomocysteincmia and hetcrozygosity (carrier Status) for factor V
Leiden, a rathcr common dcfcct that causcs resistance to activated
protein C. We analyzed this intcraction by calculating univariatc odds
ratios for thrombosis m persons with both or cithcr öl thrsc risk fac-
tors, äs compared with persons with neithcr risk faclor.
RESULTS
Thc ralio of male lo fcmale subjects among both thc
casc paticnts and the controls was 1:1.3, and the mcan
age was 44 years (ränge, 16 to 70 for the case patients
and 16 to 71 for thc controls); both thcse variables were
uscd in matching thc case patients and the controls.
Thc median plasma homocystcinc Icvcl in thc pa-
tients was 12.9 μηιοί per litcr (ränge, 4.8 to 60.2), and
that in the controls was 12.3 /xmol per liter (ränge, 6.4
to 37.5). The homocystcine concentrations of individual

















Figure 1. Plasma Homocysteine Levels in 269 Patients with
Deep-Vein Thrombosis and 269 Controls.
Values shown have been rounded.
Thc 95th perccntilc of thc homocystcinc Icvcls in the
control group was 18.5 μιτιοί per litcr. Of thc 269 pa-
tients, 28 (10 pcrcent) exceeded this cutoff, äs com-
pared with 13 (5 percent, by definition) in the control
group. The matched odds ratio for decp-vcin thrombo-
sis in subjects with a homocysteinc concentration abovc
the 95th perccntilc, äs compared with those whose ho-
mocysteinc Icvcls were at or below that value, was 2.5
(95 percent confidcnce intcrval, 1.2 to 5.2). Whcn thc
cutoff was set at thc 90th pcrcentilc, thc matchcd odds
ratio was 1.9 (95 percent confidence interval, 1.1 to 3.3);
it was 4.0 (95 percent confidence interval, 1.4 to 12.0)
whcn the cutoff was the 97.5th pcrccntile (Tablc 1).
In order to evaluate the possibility of a dose—rcsponsc
relation, we stratificd thc paticnts and controls accord-
ing to their homocysteine concentrations and calculated
odds ratios for thrombosis in thc paticnts at thc higher
levels äs compared with thosc at the lowest level. As
Figurc 2 shows, the risk of thrombosis did not increase
among subjects with homoeysteinc levels up to 18 μιτιοί
per liter; the risk was greatly increased abovc 22 μηιοί
per liter, howevcr, inclicating a thrcshold effcct rathcr
than a continuous dose—rcsponsc rclation.
Odds ratios for several age groups and for men and
women separately arc shown in Table 2. For both scxcs,
there was a sharp increase in thc risk of thrombosis as-
sociatcd with hypcrhomocysteincmia at inereasing ag-
es. The overall odds ratio for thrombosis associatcd with
hyperhomocysteinemia in women was 7.0 (95 percent
confidence intcrval, 1.6 to 30.8), and in men it was 1.4
(95 percent confidence intcrval, 0.6 to 3.4), with the
cutoff sct at thc 95th perccntilc of the homocysteine
levels in thc control group (P = 0.067 for thc compari-
son between the sexcs). Whcn wc calculated thc 95th
pcrccntile of thc distribulion of homocystcinc levels for
men and womcn separately, wc found a 95th percentilc
of 17.1 μπιοί per liter among women and 20.0 μιτιοί per
liter among men in thc control group. Using thcsc cut-
offs for hypcrhomocystcincmia, we found an odds ratio
for thrombosis of 3.8 (95 percent confidence intcrval,
1.4 to 10.2) for womcn and 1.8 (95 percent confidence
intcrval, 0.6 to 5.4) for men.
Thc higher rate of hyperhomocysteinemia in wom-
en than in men was prcscnl al all agcs, making it un-
likcly thal thc diffcrence was cluc to risk factors spe-
cific to women, such äs thc use of oral contraccptivcs,
rccenf childbirth, or prcgnancy. Indecd, whcn we cx-
cluclcd womcn wilh thcse risk factors, the unmatchcd
odds ratio for thrombosis that was associated wilh hy-
pcrhomocystcincmia (with the 95th pcrccntile ihr hol h
sexes — 18.5 μηιοί per litcr — äs the cutoff for hyper-
homocysleincmia) among women under thc age of 50
was 11.3 (95 perccnl confidence intcrval, 2.7 to 46.0),
whcrcas it was 2.8 (95 percent confidenee interval, 0.9
to 8.7) for all women, both those wilh and l hose with-
out thcsc risk factors, under llic age of 50.
Of thc 269 palienls, 15 hacl prolein C deficirney, 7 h ad
protein S deiicienry, and 10 hacl antithrombin dcficicn-
cy. In the control group, 1'our hat! prolcin C dcficicncy,
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Table 1. Pairwise Distribution of Plasma Ho-
mocysteine Values in 269 Gase Patients and
Their Matched Controls, According to Vari-
ous Definitions of Hyperhomocysteinemia.*
CUTOTT 90τπ PCRCCNIILE (]6 6 μηιοί per l iter)
CASC PATIENTS CON1RO1S
Abovc cutoff Below cutoff




Matched odds lal io foi thrombosis,
I 9 (95% CI, l 1-33)
Cuion 9 5 i i ] Pi RC f N I I I ϊ ( 1 8 5 μηιοί pci l i t e r )
C A S I P A I I F N I S CONTRO1 S
Above cutoff Below cutofi
Above culoff
Bciow cutofi
Matched odds lat io for thrombosis,
2 5 (95% CI, l 2-5 2)
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Matched odds lat io foi thiombosis.
40(95%CI, 3 4-120)
^Füi cach cutolf point, subjccts classihcd äs ha\mg hypciho-
mocystcmemia weie thosc with plasma homocyslcmc 3c\els
above the culoll value, and subjects elassified äs not having hypcr
homocystememia wcie thosc with levcls at 01 bclow thc cutoff
valuc ('below culol l ' ) Tbe pcieentiles used äs culofls were toi
(he dis t t ibut ion of bomocysteine valucs in the contiof gioup Odds
ratlos wcrc calculated äs the nsk of thiombosis in the stibjects with
hypethoinocystememia äs Lompaied with that m the subjects
withotit hypci homocystcincnua CI dcnotcs conhdcncc intcnal
cighl had protcin S dcficicncy, and cight had anlithrom-
bin deficicncy. After cxcluding thesc subjccts, we found
a matchcd odds ratio for decp-vein ihrombosis of 2.6 (95
percent confidcnce interval, 1.2 to 5.9), äs comparcd
with 2.5 (95 pcrccnt confidcnce interval, 1.2 to 5.2) \vhcn
thosc subjccts werc included; this result shows that the
cffect of homocystcine is largely indepenclent of thesc
deficicnries in clotting-factor Inhibitors.
With respect to thc combination of factor V Leiden
and hypcrhomocyslcincmia, wc calculated odds ratios for
thrombosis in subjccts with both risk factors or either onc
in rclation to subjects with ncithcr. A total of 47 of the pa-
ticnts carricd the factor V Leiden rautalion, äs comparcd
with 7 of thc controls. Thc small numbcr with both dc-
fccts madc thc results statistically unstable and some-
what sensitive to the cutoff chosen for clevalcd homocys-
teine levels. When thc 90th pcrccntilc was uscd äs thc
cutolf, thc odcLs ralio for thrombosis associated with thc
presence of bolh risk factors (factor V Leiden and hypcr-
homoeysteinernia) was 3.5 (95 percent confidcnce intci-
val, 0.7 lo 16.9); the odds ratios foi thrombosis associated
with factor V Leiden alone and hyperhomocjsleinemia
alonc, talculated sepaialely, were 9.5 and 2.2, rcspcctive-
ly. With the c)5th peicentile used äs thc cutofi, the odds
latio foi the combination of risk factois was 2.0 (95 pei-
ccnt tonddence inlcual, 0.4 to 10.9), \ \heieas the odds
ratios for cach i isk factor separately remamed virtualh
unchanged. The statistical uncertainty of results based
on these data is reflected in the wide confidence inter-
vals, which do not exclude a relative risk äs high äs 16.9.
DlSCUSSION
Our study shows that hyperhomocysteinemia is a risk
factor for deep-vein ihrombosis in the gencral popula-
tion. Moreovcr, our results suggest that thc association
between mild hyperhomocysteinemia and venous throm-
bosis is similar in degree to that reported for hyperhomo-
cysteinemia and arterial vascular discase.'1'16 An unex-
pected finding was the substantial increase in the risk of
thrombosis at the highest plasma homocysteine levels.
Our data suggest that there may be a thrcshold levcl
above which homocysteine has a thrombogcnic cffect.
Falcon et al. reported that hyperhomocysteinemia was
a risk factor for juvenile thrombosis.6 Our data imply
that hyperhomocysteinemia is a risk factor for thrombo-
sis in adult subjects äs well, since we found an increasing
odds ratio with increasing age.
When we analyzed men and women separately, we
found a differcnce in the risk of thrombosis associated
with hyperhomocysteinemia. Even when we used diffcr-
cnt cutoff points for hyperhomocysteinemia in men and
women by calculating the 95th percentiles of their ho-
mocysteine distributions in the control group separate-
ly, wc found that thc odds ratio was roughly twice äs
high for women äs for men. This suggests that women
may be more susceptible to thc pathologic effects of el-
cvatccl homocysteine levels, cven though their homocys-
teine levels arc in gencral lowcr than those of men.1 This
cffect cannot bc explained by risk factors spccific to
women (such äs pregnancy, rccent childbirth, and oral-
contraccpüve usc); an cffect of thesc risk factors was
unlikcly in any casc bccausc thc differcnce betwccn
men and women who did not havc such risk factors was
even more pronouneed.
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>22
Figure 2 Odds Ratio for Thrombosis According to Plasma Ho-
mocysteine Level.
The reference category was the subjects with plasma homocys-
teine values of <12 /tmol per liter.
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Table 2. Odds Ratlos for Thrombosis Associated
with Hyperhomocystememia, According to Age
and Sex.·1
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ΛΊΐΙι the nsk in those withoul hypcihomocystememia Cl dcnotcs conh
icnce interval
l1 he odds ratio was 12 0 (95 pcrccnt confidcncc jnlcrval ! 6 to 92 3)
λΊιεη Ihe cutoll used was thc 90th peicendlc in the c o n t i o l gioup
dccp-vcin thrombosis aftcr wc excludcd subjects with
other wcll-established risk factors; that is, the associa-
tion with thrombosis was not cxplaincd by thc prcscncc
of other hercditary risk factors for thrombosis, such äs
a dcficicncy of protem G, protem S, or antithrombin. The
same was truc of the most common hereclitary risk fac-
tor for deep vcnous thrombosis, resistancc to activalcd
protcin G, sincc hypcrhomocysteinemia also increased
thc risk of thrombosis in those without this abnormal-
ity. We investigated a possiblc interaction between re-
sistancc to activatcd protcin G (factor V Leiden) and hy-
pcrhomocysteinemia. Although we found that the risk
of thrombosis may be higher m carners of the mutation
who havc hyperhomocysteinemia than in noncarriers
with hyperhomocysteinemia, the combined effect in our
subjects seemed smaller than for factor V Leiden alonc.
Becausc of the small numbers mvolvcd, thc only rca-
sonablc conclusion is that thc two factors do not poten-
tiatc each other.
Many hypotheses have been proposed to cxplain how
hyperhomocysteinemia may lead to vcnous thrombosis
and atheiosclerosis. One hypothesis is that homocys-
teine has a toxic effect on thc vascular cndothelium and
on the clotting cascadc.1·2 Scveral in vitro studies seem
to support this view.17·18 However, virtually all these stud-
ies used amounts of homocysteine that produced high-
er-than-physiologic concentrations. Alternatively, hy-
perhomocysteinemia may reflect abnormal methiomne
metabolism that affects the methylation of DNA and
cell membranes.19
Elevated homocysteine levels may result from low lev-
els of fohc acid, vitamm B6, or vitamm B u. Moreover, sev-
eral genetic alterations in enzymes involved in homocys-
teine metabolism have been described.20 22 It remains
unclear whether hyperhomocysteinemia of different caus-
es entails the same risk of thrombosis. Ncvertheless, it is
well knowri that vitamin supplementation lowers ho-
mocysteine concentrations in almost all subjects with hy-
perhomocysteinemia, rcgardlcss of thc undcrlying causc.
We conclude that mild hyperhomocysteinemia is a
risk factor for deep-vein thrombosis in the general pop-
ulation. The ncxt question to be answercd is whether
homocystcine-lowering therapy — folic acid, Vitamin
B6, or vitamin B
currcnt vcnous thrombosis.2
Wc arc tndcbtcd to Mi s T Vissci, Mi s A. \ an Bc< k, Mi s M T WB
Ic Poik-l-Otholl, and Mis A de Giaal-Ikss lui ihon ( \ c r l l i n t as-
sistanco
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